Rigel Pharmaceuticals Files 8-K on Financials
Ticker: RIGL · Form: 8-K · Filed: Nov 7, 2024 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 8-K |
| Filed Date | Nov 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: RIGL
TL;DR
Rigel dropped an 8-K on Nov 7th about their financials - check it for the deets.
AI Summary
Rigel Pharmaceuticals, Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signals that Rigel Pharmaceuticals is providing updated operational and financial information to the SEC, which is crucial for investors to assess the company's current standing.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial information and does not inherently contain negative news or significant changes.
Key Players & Entities
- RIGEL PHARMACEUTICALS, INC. (company) — Registrant
- November 7, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 611 Gateway Boulevard Suite 900 (address) — Principal executive offices
- South San Francisco (location) — City of principal executive offices
- CA (state) — State of principal executive offices
- 94080 (zip_code) — Zip code of principal executive offices
- ( 650 ) 624-1100 (phone_number) — Registrant's telephone number
FAQ
What specific financial results or conditions are being reported in this 8-K?
The provided text of the 8-K filing indicates it is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail the specific figures or conditions within the excerpt.
When was this 8-K filing submitted to the SEC?
The filing was submitted on November 7, 2024, as indicated by the 'Date of Report (Date of earliest event reported)' and 'FILED AS OF DATE'.
What is the principal business address of Rigel Pharmaceuticals, Inc.?
The principal executive offices are located at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is the Commission File Number for Rigel Pharmaceuticals, Inc.?
The Commission File Number for Rigel Pharmaceuticals, Inc. is 0-29889.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-11-07 16:22:30
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar
Filing Documents
- tm2427717d1_8k.htm (8-K) — 25KB
- tm2427717d1_ex99-1.htm (EX-99.1) — 94KB
- 0001104659-24-115334.txt ( ) — 304KB
- rigl-20241107.xsd (EX-101.SCH) — 3KB
- rigl-20241107_lab.xml (EX-101.LAB) — 33KB
- rigl-20241107_pre.xml (EX-101.PRE) — 22KB
- tm2427717d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On November 7, 2024, Rigel Pharmaceuticals, Inc. (" Rigel ") announced certain financial results for its third quarter ended September 30, 2024. A copy of Rigel's press release, titled "Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update," is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Rigel, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release, dated November 7, 2024, titled "Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 7, 2024 RIGEL PHARMACEUTICALS, INC. By: /s/ Raymond J. Furey Raymond J. Furey Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary